The conventional view of skeletal muscle as a passive tissue involved mainly in movement and metabolism is increasingly giving way to a more dynamic picture: muscle as an endocrine organ that actively broadcasts longevity signals throughout the body. A newly characterized secreted protein called Mimecan may be one of the most compelling candidates yet identified in this emerging framework, with implications for understanding why aging accelerates when muscle mass and function decline.
Published in Cell Metabolism, this study identified Mimecan through transcriptomic comparisons of young versus aged skeletal muscle in mice, finding that its expression falls significantly with age. Using both muscle-specific loss- and gain-of-function models, researchers demonstrated that circulating Mimecan acts on melanocortin 4 receptor (MC4R)-expressing neurons in the dorsomedial hypothalamus (DMH) and dorsal hypothalamic area (DHA). The mechanism depends on Mimecan's ability to maintain primary cilia on these neurons — sensory organelles essential for signal transduction — which in turn amplifies sympathetic nervous output to brown adipose tissue (BAT), elevating core body temperature. Critically, targeted Mc4r knockdown specifically in DMH/DHA neurons completely abolished Mimecan's thermogenic effects, confirming pathway specificity. Restoring circulating Mimecan levels in aged mice significantly extended lifespan, not merely a health metric.
This finding is potentially paradigm-shifting for several reasons. It places a myokine at the center of a three-organ longevity circuit — muscle, hypothalamus, and BAT — previously not known to be linked through a single secreted factor. The primary cilia mechanism is particularly noteworthy; ciliopathies are already linked to metabolic disease, and cilia loss in hypothalamic neurons may be an underappreciated aging mechanism. The lifespan extension in aged animals — rather than simply young ones — is the critical translational signal here. Major limitations include the exclusively murine evidence base, the lack of defined human Mimecan aging trajectories in large cohorts, and uncertainty about whether pharmacological restoration of circulating Mimecan would be feasible or safe in humans. Still, as an incremental-to-paradigm-shifting finding, this ranks toward the higher end.
